News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Alchemia Release: Significant Milestone on Path to Commercialisation of Fondaparinux


12/17/2008 9:41:10 AM

BRISBANE, Australia--(BUSINESS WIRE)--Australian drug developer, Alchemia Limited (ASX:ACL), today announced the achievement of a significant milestone towards the commercialisation of its lead product, generic fondaparinux. As a consequence, Alchemia will receive payments from its manufacturing and marketing partner Dr Reddy’s Limited (DRL) totaling US$1,625,000 (A$2,400,000). US$1 million will be received in December 2008 and a further US$625,000 upon the earlier of the approval of the Abbreviated New Drug Application (ANDA) and 31 December 2009.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES